Neoplasia 2(4): 291-299

Cell Cycle and Apoptosis<sup><a href="#FN1" rid="FN1" class=" fn">1</a></sup>

Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Suite 226, 1020 Locust Street, Philadelphia, PA 19107

Address all correspondence to: Antonio Giordano, MD, PhD, Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, JAH Room 226, Philadelphia, PA 19107. E-mail: ude.ujt.icj.cal@nadroiga

Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Suite 226, 1020 Locust Street, Philadelphia, PA 19107

Received 1999 Sep 3; Revised 2000 Jul 7; Accepted 2000 Jul 10.

Abstract

In multicellular organisms, cell proliferation and death must be regulated to maintain tissue homeostasis. Many observations suggest that this regulation may be achieved, in part, by coupling the process of cell cycle progression and programmed cell death by using and controlling a shared set of factors. An argument in favor of a link between the cell cycle and apoptosis arises from the accumulated evidence that manipulation of the cell cycle may either prevent or induce an apoptotic response. This linkage has been recognized for tumor suppressor genes such as p53 and RB, the dominant oncogene, c-Myc, and several cyclin-dependent kinases (Cdks) and their regulators. These proteins that function in proliferative pathways may also act to sensitize cells to apoptosis. Indeed, unregulated cell proliferation can result in pathologic conditions including neoplasias if it is not countered by the appropriate cell death. Translating the knowledge gained by studying the connection between cell death and cell proliferation may aid in identifying novel therapies to circumvent disease progression or improve clinical outcome.

Keywords: apoptosis, cell cycle, c-myc, p53, pRb, Cdks

Abstract

Acknowledgements

The authors thank Marco Tafani for critically reading the manuscript and for his comments. M. K. was supported by NCI training grant 5 T32 CA 09137.

Acknowledgements

Footnotes

^{This work was supported by grants from the National Institutes of Health awarded to A. G. and in part by The Sbarro Institute.}

Footnotes

References

1. Jacobson MD, Weil M, Raff MCProgrammed cell death in animal development. Cell. 1997;88:347–354.[PubMed][Google Scholar]
2. Wyllie AH British Medical Bulletin 53. Dorchester: The Dorset Press; 1997. Apoptosis. [PubMed][Google Scholar]
3. Golstein PControlling cell death. Science. 1997;275:1081–1082.[PubMed][Google Scholar]
4. King KL, Cidlowsky JACell cycle and apoptosis: common pathways to life and death. J Cell Biochem. 1995;58:175–180.[PubMed][Google Scholar]
5. Evan GI, Brown L, Whyte M, Harrington EApoptosis and the cell cycle. Curr Opin Cell Biol. 1995;7:825–834.[PubMed][Google Scholar]
6. MacLachlan TK, Sang N, Giordano ACyclins, cyclin-dependent kinases and Cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryotic Gene Expression. 1995;5:127–156.[PubMed][Google Scholar]
7. Harper JW, Elledge SJCdk inhibitors in development and cancer. Curr Opin Genet Dev. 1996;6:56–84.[PubMed][Google Scholar]
8. Riley DJ, Lee EY-HP, Lee WHThe retinoblastoma protein: more than a tumor suppressor. Annu Rev Cell Biol. 1994;10:1–29.[PubMed][Google Scholar]
9. Sidle A, Palaty C, Dirks P, Wiggan O, Kiess M, Gill RM, Wong AK, Hamel PAActivity of the retinoblastoma family proteins, pRb, p107 and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol. 1996;31:237–271.[PubMed][Google Scholar]
10. Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S, Dean DCMechanism of active transcriptional repression by the retinoblastoma protein. Nature. 1995;375:812–815.[PubMed][Google Scholar]
11. Lam EW, La Thangue NBDP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol. 1994;6:859–866.[PubMed][Google Scholar]
12. Amati B, Littlewood TD, Evan GI, Land HThe c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 1993;12:5083–5087.[Google Scholar]
13. Heikkila R, Schwab G, Wichstrom E, Loke SL, Pluznik DH, Watt R, Nackars LMA c-myc antisense oligodeoxynucleotide inhibits entry into S-phase but not progress from G0 to G1. Nature. 1987;328:445–449.[PubMed][Google Scholar]
14. Graeber TG, Osmanian C, Jacks T, Houseman DE, Koch CJ, Lowe SW, Giaccia AJHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996;379:88–91.[PubMed][Google Scholar]
15. Wagner AJ, Small MB, Hay NMyc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol. 1993;13:2432–2440.[Google Scholar]
16. Galaktionov K, Chen X, Beach DCdc25 cell cycle phosphatases as a target of c-myc. Nature. 1996;382:511–517.[PubMed][Google Scholar]
17. Levine A. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331.[PubMed]
18. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, Deppert WNegative feedback regulation of wild-type p53 synthesis. EMBO J. 1995;14:4442–4449.[Google Scholar]
19. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GRThe p53 network. J Biol Chem. 1998;273:1–4.[PubMed][Google Scholar]
20. Schneider E, Montenarh M, Wagner PRegulation of CAK kinase activity by p53. Oncogene. 1998;17:2733–2741.[PubMed][Google Scholar]
21. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 1995;92:8493–8497.
22. Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA. 1999;96:2147–2152.
23. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B14-3-3 Sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997;1:3–11.[PubMed][Google Scholar]
24. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GMDNA re-replication in presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 1997;57:1013–1019.[PubMed][Google Scholar]
25. Brown CR, Doxsey SJ, White, Welch WJBoth viral (adenovirus E1B) and cellular (hsp70, p53) components interact with centrosomes. J Cell Physiol. 1994;160:47–60.[PubMed][Google Scholar]
26. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GFAbnormal centrosome amplification in the absence of p53. Science. 1996;271:1744–1747.[PubMed][Google Scholar]
27. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren MInduction of apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev. 1995;9:2170–2183.[PubMed][Google Scholar]
28. Miyashita T, Harigai M, Hanada M, Reed JCIdentification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131–3135.[PubMed][Google Scholar]
29. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CCThe XPB and XPD DNA helicases are components of the p53-mediated apoptosis. Genes Dev. 1996;10:1219–1232.[PubMed][Google Scholar]
30. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky RWild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995;15:3032–3040.[Google Scholar]
31. Wu GS, Burns TF, McDonald ER, III, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141–143.[PubMed]
32. Polyak K, Waldman T, He TC, Kinzlre KW, Vogestein BGenetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 1996;10:1945–1952.[PubMed][Google Scholar]
33. Debbas M, White EWild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 1993;7:546–554.[PubMed][Google Scholar]
34. Chiou SK, Rao L, White EBcl-2 blocks p53-dependent apoptosis. Mol Cell Biol. 1994;14:2556–2563.[Google Scholar]
35. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrel M, Hill DE, Wang Y, et al WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169–1174.[PubMed][Google Scholar]
36. Sherr CJTumor surveillance via the ARF-p53 pathway. Genes Dev. 1998;12:2984–2991.[PubMed][Google Scholar]
37. Jacks T, Fazeli A, Schmitt E, Branson R, Goodell M, Weinberg REffects of an Rb mutation in the mouse. Nature. 1992;359:295–300.[PubMed][Google Scholar]
38. Fan G, Ma X, Kren BT, Steer CJThe retinoblastoma gene product inhibits TGF-β1 induced apoptosis in primary rat hepatocytes and in human HuH-7 hepatoma cells. Oncogene. 1996;12:1909–1919.[PubMed][Google Scholar]
39. Berry DE, Lu Y, Schmidt B, Fallon PG, O'Connell, Hu SX, Xu HJ, Blanck GRetinoblastoma protein inhibits IFNγ-induced apoptosis. Oncogene. 1996;12:1809–1819.[PubMed][Google Scholar]
40. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'ang A, Fung YK, Israel MAInhibition of apoptosis by the retinoblastoma gene product. EMBO J. 1995;14:461–472.[Google Scholar]
41. An B, Dou QPCleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as a candidate. Cancer Res. 1996;56:438–442.[PubMed][Google Scholar]
42. Dou QP, An B, Antoku K, Johnson DEFas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J Cell Biochem. 1997;64:586–594.[PubMed][Google Scholar]
43. Janicke RU, Walker PA, Lin XY, Porter AGSpecific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J. 1996;15:6969–6978.[Google Scholar]
44. Erhardt P, Tomaselli KJ, Cooper GMIdentification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem. 1997;272:15049–15052.[PubMed][Google Scholar]
45. Williams BO, Remington L, Albert DM, Mukai S, Branson RT, Jacks TCooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994;7:480–484.[PubMed][Google Scholar]
46. Pan H, Griep EAltered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implication for tumor suppressor gene function in development. Genes Dev. 1994;8:1285–1299.[PubMed][Google Scholar]
47. Fromm L, Shawlot W, Gunning K, Butel JS, Overbeek PAThe retinoblastoma binding region of simian virus 40 large T antigen alters cell cycle regulation in lenses of transgenic mice. Mol Cell Biol. 1994;14:6743–6754.[Google Scholar]
48. McCarthy SA, Symonds HS, Van Dyke TRegulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc Natl Acad Sci USA. 1994;92:3979–3983.[Google Scholar]
49. Lee MH, Williams BO, Mulligan G, Mukai S, Branson RT, Kyson N, Harlow E, Jacks TTarget disruption of p107: functional overlap between p107 and pRb. Genes Dev. 1996;16:1621–1632.[PubMed][Google Scholar]
50. Harvey KJ, Blomquist JF, Ucker DSCommitment and effector phases of physiological cell death pathway elucidated with respect to Bcl-2, caspase and cyclin-dependent kinase activities. Mol Cell Biol. 1998;18:2912–2922.[Google Scholar]
51. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee ABInduction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science. 1995;268:429–431.[PubMed][Google Scholar]
52. Meikrantz W, Gisselbrecht S, Tam S, Schlegel RActivation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA. 1994;91:3754–3758.[Google Scholar]
53. Gil-Gomez G, Berns A, Brady HJMA link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J. 1998;17:7209–7218.[Google Scholar]
54. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WGSelective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonist. Proc Natl Acad Sci USA. 1999;13:4221–4223.[Google Scholar]
55. Kasten MM, Giordano ApRb and the cdks in apoptosis and the cell cycle. Cell Death Differ. 1998;5 1342-140. [[PubMed][Google Scholar]
56. Ling YH, Consoli U, Tornos C, Andreef M, Perez-Soler RAccumulation of cyclin B, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer. 1998;75:925–932.[PubMed][Google Scholar]
57. Lahti JM, Xiang J, Heath LS, Campana D, Kidd VJPITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol. 1995;15:1–11.[Google Scholar]
58. Beyaert R, Kidd VJ, Cornelis S, Van de Craen M, Denecker G, Lahiti JM, Gururajan R, Vandenabeele P, Fiers WCleavage of PITSLRE kinases by ICE/CASP1 and CPP32/CASP3 during apoptosis induced by tumor necrosis factor. J Biol Chem. 1997;272:11694–11697.[PubMed][Google Scholar]
59. Tang D, Gururajan R, Kidd VJPhosphorylation of PITSLRE p110 isoforms accompanies their processing by caspases during Fas-meditated cell death. J Biol Chem. 1998;273:16601–16607.[PubMed][Google Scholar]
60. Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W, Weinsten IBIncreased expression of cyclin D1 in a murine mammary epithelial cell line induces p27Kip1, inhibits growth and enhanced apoptosis. Cell Growth Differ. 1996;7:699–710.[PubMed][Google Scholar]
61. Janicke RU, Lin XY, Porter AGCyclin D3 sensitizes tumor cells to TNF-induced, c-Myc-dependent apoptosis. Mol Cell Biol. 1996;16:5245–5253.[Google Scholar]
62. Wang J, Walsh KResistance to apoptosis conferred by CDK inhibitors during myocyte differentiation. Science. 1996;273:359–361.[Google Scholar]
63. Poluha W, Poluha D, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL, Ross AHThe cyclin-dependent kinase inhibitor p21WAF1 is required for survival of differentiating neuroblastoma cells. Mol Cell Biol. 1996;16:1335–1341.[Google Scholar]
64. Lu Y, Yamagishi N, Yagi T, Takebe HMutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene. 1998;16:705–712.[PubMed][Google Scholar]
65. Wang X, Gorospe M, Huang Y, Holbrook NJp27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene. 1997;15:2991–2997.[PubMed][Google Scholar]
66. Scott DW, Donjerkovic D, Maddox B, Ezhevsky S, Grdina TRole of c-myc and p27 in anti-IgM-induced B-lymphoma apoptosis. Curr Topics Microbiol Immunol. 1997;224:102–112.[PubMed][Google Scholar]
67. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJModulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1) J Clin Invest. 1999;103:597–604.[Google Scholar]
68. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Russel RCleavage of p21^{and p27}^{mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade.}Mol Cell. 1998;1:553–563.[PubMed][Google Scholar]
69. Gervais JLM, Seth P, Zhang HCleavage of CDK inhibitor p21^{by caspases is an early event during DNA damage-induced apoptosis.}J Biol Chem. 1998;273:19207–19212.[PubMed][Google Scholar]
70. Donato N, Perez MTumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J Biol Chem. 1998;273:5067–5072.[PubMed][Google Scholar]
71. Loubat A, Rochet N, Turchi L, Rezzonico R, Far DF, Auberger P, Rossi B, Ponzio GEvidence for a p23-caspase-cleaved form of p27(KIP1) Oncogene. 1999;18:3324–3333.[PubMed][Google Scholar]
72. Yan Y, Friesen J, Lee MH, Massague J, Barbacid MAblation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11:973–983.[PubMed][Google Scholar]
73. Hama S, Heike Y, Naruse I, Takahashi M, Yoshioka H, Arita K, Kurisu K, Goldman CK, Curie DT, Saijo NAdenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer. 1998;77:47–54.[PubMed][Google Scholar]
74. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss MAdenoviral-transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 1997;3:313–319.[PubMed][Google Scholar]
75. Schreiber M, Muller WJ, Singh G, Graham FLComparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21 (WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene. 1999;18:1663–1676.[PubMed][Google Scholar]
76. Pucci B, Giordano ACell cycle and cancer. Clin Ter. 1999;150:135–141.[PubMed][Google Scholar]